Claims for harm from Allergan implants

Who may qualify?

If you have Allergan implants and a BIA-ALCL diagnosis, ask a lawyer to check your facts. BIA-ALCL is a cancer of the immune system, not breast cancer. A device record and your health records are useful starting points for that discussion.

Do not guess at the brand or model based on how the implant feels. The patient device card can show the style, size and serial or lot number. If you cannot find it, ask the surgeon or facility for the operation notes. Tell the lawyer which details you have and which are still missing.

The 2019 recall covered certain BIOCELL textured implants and tissue expanders. A tissue expander is a device in the recalled product list, not the name of a cancer. If you had more than one implant operation, collect the records for each. Ask how your device history, diagnosis and dates affect a possible claim.

What could I get?

A recall notice does not state a payment for each patient. The cited court orders address court procedure, not an award for you. Ask what a quoted sum covers and what document supports it. AbbVie's Q2 2026 report says it agreed in June to resolve substantially all U.S. BIA-ALCL lawsuits. As of October 6, 2026, ask your lawyer whether that agreement covers your claim.

Keep the medical and billing records that describe what happened to you. Federal health privacy guidance generally gives you a right to copies from covered providers, with exceptions. These records can help you explain your care and costs. Ask a lawyer which records are useful before paying to request a large set. Do not use an online payout range to plan your finances.

A medical bill and a law firm’s expense bill are different questions. Ask which health costs your insurer covers. FDA guidance warns that some insurers do not cover implant removal or replacement, even with complications. Ask the firm separately about its fees and case expenses. Neither discussion is a guarantee of money from a claim.

Is there a deadline?

Ask for a check of your own filing time limit now. The rule depends on the law and the type of claim. A pretrial date in the Allergan court is not a deadline for every patient.

The federal court in New York explains that legal time limits can require checking both federal and state law. Its general guidance does not give one date for all implant claims. Write down the dates of each operation, symptom, diagnosis and any prior legal filing. Mark dates you do not know instead of filling them in from memory. Ask which event starts the clock in your situation.

The FDA asked for the recall on July 24, 2019. That is the date of a safety action, not a universal legal filing deadline. Tell the lawyer when you learned which device you had and when you learned about your health concern. Ask about your own time limit even if the implant was removed years ago.

What happens after I check?

Use the first discussion to ask which device records, health facts and dates need review. Ask about the filing limit and written fees. Get clear answers before signing a representation agreement.

Start with the records you have, not a guessed diagnosis. Ask which person or firm will review your facts and how to reach them. Ask who may receive your information and what permission you are giving. If someone offers a fast reply or a free review, ask for those terms before relying on them. If a lawyer already represents you, tell the new firm before signing anything. Keep a copy of what you sign.

The federal proceedings have master docket number 2:19-md-2921 in New Jersey. The court lists Brian R. Martinotti as district judge and Leda Dunn Wettre as magistrate judge. This identifies the court, not a firm’s intake rules. Ask how any proposed claim relates to that docket and which rules apply to you.

Questions people ask

The answers below distinguish the Allergan recall, BIA-ALCL and other cancer reports. Use your own implant records when asking about a claim. Keep medical care and legal advice as separate questions for the right professionals.

How Allergan BIOCELL Textured Implants Cause BIA-ALCL and Breast Implant Illness

Allergan's BIOCELL textured breast implants — marketed under the Natrelle brand — use a proprietary salt-loss texturing process that creates a uniquely aggressive surface topography. Decades of post-market surveillance and published research established that this surface sheds silicone particles, triggers chronic immune activation, and is directly associated with BIA-ALCL (Breast Implant-Associated Anaplastic Large Cell Lymphoma), a rare but potentially fatal T-cell lymphoma. Beyond lymphoma, thousands of women with textured and smooth implants report a constellation of systemic symptoms known as Breast Implant Illness (BII), driven by chronic foreign-body immune response and silicone particle migration.

BIOCELL Salt-Loss Texturing Creates Pathologically Rough Surface

Allergan's BIOCELL texturing is manufactured via a salt-loss (polyurethane contact) process that creates a surface with a pore depth of approximately 400–600 microns — two to four times rougher than competitor textured implants (Sientra Opus, Mentor Siltex). This extreme surface area retains protein, bacteria, and cellular debris in the peri-implant space. Independent scanning electron microscopy studies have shown that BIOCELL implants shed silicone particle fragments into the surrounding tissue at measurable rates. The rough surface also impedes normal macrophage clearance, allowing shed particles and biofilm to persist chronically in the capsule.

Chronic T-Cell Stimulation and Lymphocyte Accumulation in Peri-Implant Fluid

The BIOCELL surface acts as a chronic antigenic stimulus, recruiting CD4+ T-helper cells, CD30+ T-cells, and activated macrophages into the peri-implant fluid (seroma) and fibrous capsule. This persistent immune activation — fundamentally different from the normal foreign-body response to smooth implants — creates a pro-lymphomagenic microenvironment. Pathological studies of BIA-ALCL cases consistently find a seroma effusion rich in CD30+ T-lymphocytes surrounding textured implants. The hypothesis, supported by peer-reviewed literature, is that chronic bacterial biofilm on the implant surface drives antigen-specific T-cell clonal expansion — the cellular precursor to lymphoma.

BIA-ALCL Development: CD30+/ALK- T-Cell Lymphoma in the Capsule

BIA-ALCL is a CD30-positive, anaplastic lymphoma kinase (ALK)-negative T-cell lymphoma arising in the fibrous capsule surrounding a breast implant. It is causally linked to textured breast implants — overwhelmingly Allergan BIOCELL — with over 90% of confirmed global BIA-ALCL cases associated with textured surfaces. The disease typically presents as a late-onset (median 7–10 years post-implantation) seroma effusion around the implant. In its localized form, confined to the seroma and capsule, BIA-ALCL is curable with implant and capsule removal (total capsulectomy). In its infiltrative form — involving invasion of surrounding breast tissue, lymph nodes, or distant organs — it requires chemotherapy and carries a significantly higher mortality risk. FDA's medical device report summary lists 64 U.S. and worldwide deaths reported as of June 30, 2024.

Capsular Contracture: Fibrous Encapsulation and Implant Deformity

Capsular contracture — the hardening and distortion of the fibrous capsule surrounding a breast implant — occurs at higher rates in textured implants following capsule disruption and in smooth implants subjected to chronic low-grade infection or silicone bleed. In the context of Allergan BIOCELL implants, the roughened surface's propensity for biofilm formation and chronic inflammation accelerates capsular fibrosis. Severe capsular contracture (Baker Grade III–IV) causes breast pain, visible implant distortion, rippling, and palpable hardening. Surgical correction requires capsulectomy — complete or partial removal of the capsule — often with simultaneous implant exchange, carrying full surgical risks.

Breast Implant Illness (BII): Systemic Symptoms of Chronic Immune Dysregulation

Breast Implant Illness is a patient-reported syndrome encompassing fatigue, joint pain, cognitive dysfunction (brain fog), hair loss, rash, dry eyes, thyroid dysfunction, and autoimmune-like symptoms in women with breast implants — both textured and smooth, saline and silicone. BII is not yet a formal ICD-coded diagnosis, but a growing body of peer-reviewed literature and FDA advisory panel testimony supports the biological plausibility of systemic immune dysregulation from silicone particle migration, silicone gel bleed through the implant shell, and chronic foreign-body immune activation. Many women report dramatic symptom resolution following explantation (implant removal with total capsulectomy), which supports the causal relationship between implants and systemic illness.

• BIOCELL Texturing — Uniquely High Surface Roughness: The BIOCELL manufacturing process produces a surface roughness 2–4x greater than all other textured implant systems commercially available. This is a specific design characteristic of Allergan's process, not a universal property of textured implants. Studies comparing BIA-ALCL incidence by implant surface type consistently find that BIOCELL implants carry the highest per-implant risk — estimated at 1 in 2,000 to 1 in 86,000 depending on study methodology, versus near-zero incidence for smooth implants. The surface roughness is the primary driver of pathological peri-implant immune activation.
• Duration of Implantation — Risk Increases with Time In-Situ: BIA-ALCL risk increases significantly with implant duration. The median time from implantation to BIA-ALCL diagnosis is 7–10 years, with cases reported up to 28 years post-implantation. Women who had BIOCELL implants placed between 1998 and 2019 (when the recall occurred) and who have not had them removed remain at elevated risk. The cumulative immune stimulation over years creates the clonal T-cell expansion environment that precedes lymphoma development. Annual clinical follow-up and prompt evaluation of new-onset seroma are critical for women who retain recalled implants.
• Allergan's Failure to Act on Its Own BIA-ALCL Surveillance Data: Internal Allergan vigilance reports document that the company was aware of BIA-ALCL cases associated with BIOCELL implants as early as 2011. Despite accumulating case reports in its pharmacovigilance database, Allergan did not proactively notify physicians, regulators, or patients of the emerging signal. It continued to market and sell BIOCELL implants — including Natrelle 410 cohesive gel implants (the most widely implanted textured device in the U.S.) — until the FDA demanded the July 2019 worldwide recall. Plaintiffs allege that Allergan's concealment of known BIA-ALCL risk directly caused harm to women who would have chosen alternative implants had the risk been disclosed.
• Late Detection and Misdiagnosis of BIA-ALCL as Benign Seroma: BIA-ALCL frequently presents as a new-onset seroma — fluid accumulation around the implant — which is commonly misattributed to benign causes such as minor trauma, post-operative healing, or implant micro-leakage. Without clinician awareness of BIA-ALCL, the seroma may be drained without cytological analysis of the fluid — missing the CD30+ lymphocyte population that confirms the diagnosis. Diagnostic delay allows BIA-ALCL to progress from its localized, surgically curable form to an infiltrative form requiring systemic chemotherapy. The National Comprehensive Cancer Network (NCCN) and FDA now recommend that any late-onset seroma around a breast implant be sent for cytological analysis including CD30 immunostaining.
• BIA-ALCL is causally associated with textured breast implants, with Allergan BIOCELL implants implicated in over 90% of confirmed global cases, per FDA and peer-reviewed medical literature.
• The 2019 worldwide recall of Allergan BIOCELL implants was the first mandatory breast implant recall in U.S. history, triggered by the FDA's determination that the benefit-risk profile of BIOCELL implants was unacceptable.
• Breast Implant Illness symptoms — including fatigue, cognitive dysfunction, joint pain, and autoimmune-like symptoms — are reported by a significant subset of women with breast implants, and explantation frequently produces symptom improvement.
• Women with Allergan BIOCELL implants who develop a new late-onset seroma should be evaluated immediately for BIA-ALCL, with cytological analysis including CD30 immunostaining of any drained fluid, per NCCN guidelines.

The harm mechanism evidence in Allergan breast implant litigation is unusually direct: Allergan's own internal vigilance reports, the FDA recall letter, and the medical literature collectively establish that Allergan knew about the BIA-ALCL signal years before the recall and continued marketing BIOCELL implants without adequate warning. Plaintiffs with BIA-ALCL have the strongest claims — they bear a diagnosed cancer directly traceable to Allergan BIOCELL implants. Women with systemic BII symptoms and explantation injuries (surgical risks of removal) also have actionable claims rooted in Allergan's failure to warn and the defective design of the BIOCELL surface.

Breast Implant Illness (BII)

Breast implant illness (BII) is a term used to describe a constellation of systemic symptoms that some patients with breast implants — both textured and smooth — report and attribute to their implants. Unlike BIA-ALCL, BII is not currently recognized as a single formal medical diagnosis by the FDA or the National Institutes of Health, though both agencies acknowledge reported associations. Symptoms span multiple organ systems and can include severe fatigue, joint and muscle pain, cognitive impairment, hair loss, skin rashes, and autoimmune-like reactions. The legal pathway for BII claims in MDL 2921 is distinct from BIA-ALCL claims and faces greater scientific scrutiny regarding causation, but BII plaintiffs with Allergan BIOCELL implants are included in the litigation.

• Severe chronic fatigue unrelated to other conditions
• Joint and muscle pain (polyarthralgia, myalgia)
• Cognitive impairment — brain fog, memory problems, difficulty concentrating
• Hair loss (diffuse alopecia)
• Skin rashes and hypersensitivity reactions
• Dry eyes, dry mouth, sicca syndrome
• Autoimmune-like symptoms: Hashimoto's, lupus-like presentation
• Textured or smooth breast implants (BII reported across implant types)
• Silicone gel implant shell breach or gel bleed
• Prolonged implant duration without routine monitoring
• Underlying autoimmune predisposition or HLA genetic susceptibility
• Delayed explantation after symptom onset
• Explantation (implant removal) — reported by many patients to resolve or improve BII symptoms
• En bloc capsulectomy for more complete capsule removal
• Immunological workup (ANA panel, thyroid panel, rheumatology evaluation)
• Symptom management: anti-inflammatory medications, fatigue management
• Monitoring for autoimmune disease development post-explant
• Psychological support and counseling for chronic illness impact

Allergan's Corporate Knowledge and Accountability — BIOCELL Breast Implant Litigation

Allergan PLC, the manufacturer of BIOCELL textured breast implants, has faced significant corporate accountability for its handling of BIA-ALCL risk since the condition first appeared in its pharmacovigilance systems. Internal company records produced in MDL 2921 discovery document a pattern: Allergan's vigilance team received BIA-ALCL case reports as early as 2011, accumulated a growing surveillance file over eight years, and continued aggressively marketing BIOCELL's Natrelle brand to plastic surgeons without updating patient-facing risk information.

Allergan's Pattern of Prioritizing Sales Over Patient Safety

Internal documents produced in MDL 2921 discovery, combined with Allergan's public conduct during the regulatory process, have formed the factual core of plaintiffs' punitive damages arguments. The pattern that emerges — tracking BIA-ALCL since 2011, participating in FDA advisory meetings while continuing BIOCELL sales, and initially declining the FDA's recall recommendation — reflects what plaintiffs characterize as a deliberate decision to protect a profitable product line at the expense of patient health.

• Allergan's internal vigilance reports documented BIA-ALCL cases as early as 2011 — eight years before the recall — without updating physician communications or patient labeling to reflect the lymphoma risk.
• Allergan sales representatives continued promoting BIOCELL implants' premium positioning to plastic surgeons during the period when internal pharmacovigilance files were tracking a growing BIA-ALCL signal.
• Allergan initially declined the FDA's recommendation to recall BIOCELL implants in July 2019, forcing the FDA to invoke mandatory recall authority — an unusual regulatory confrontation that plaintiffs cite as evidence of corporate bad faith.
• Women in countries outside the U.S. continued receiving BIOCELL implants after the WHO and some national regulators had raised BIA-ALCL concerns, as Allergan's market withdrawal in those jurisdictions lagged behind domestic actions in Australia, France, and Canada.

Moody's

AbbVie Ba1 Outlook Stable (2021) — BIOCELL Litigation Reserves Noted

AbbVie's post-acquisition credit profile reflected litigation reserves for BIOCELL exposure. Moody's acknowledged the liability as manageable given AbbVie's scale and Humira revenue, but noted it as a contingent liability in AbbVie's long-term obligation assessment.

S&P Global

AbbVie BBB+ Affirmed — BIOCELL Litigation Factored into Rating

S&P Global's AbbVie rating affirmed post-acquisition acknowledged the BIOCELL litigation exposure. S&P analysts noted that the scale of MDL 2921 was a negative credit factor partially offset by AbbVie's strong free cash flow and diversified pharmaceutical revenue base.

The Allergan BIOCELL breast implant litigation presents one of the most clearly documented corporate-knowledge timelines in recent medical device litigation history: internal records show Allergan tracking BIA-ALCL for eight years before the recall while marketing BIOCELL as a premium product. A July 14, 2026 court order (CMO 42) set pretrial deadlines for the first two bellwether cases, Henson and Rabin, including a final pretrial conference on October 6, 2026. Later orders may change that schedule. AbbVie's quarterly report for the period ended June 30, 2026 says that in June 2026 it reached an agreement to resolve substantially all U.S. lawsuits alleging BIA-ALCL; it reports about 1,300 other lawsuits coordinated in MDL 2921 and gives no settlement amount.

Allergan Breast Implant Lawsuit Filing Deadlines — State Statutes of Limitations

The statute of limitations for Allergan breast implant claims is typically 2 to 3 years from the date of BIA-ALCL diagnosis — or from the date a claimant knew or reasonably should have known that their Allergan BIOCELL implants caused their injury. Most states apply a discovery rule in medical device injury cases, meaning the limitations clock begins when the claimant discovered, or should have discovered, the connection between their implants and their injury — not the date of implant placement.

Discovery Rule and the July 2019 Recall as Notice Date

The July 24, 2019 worldwide recall is the most significant date for statute of limitations purposes. The recall placed all implant recipients on notice that BIOCELL implants posed a BIA-ALCL risk. In many states, a 2-year statute of limitations from the recall date would have expired July 2021; a 3-year statute expired July 2022. However, the discovery rule provides important protection: for patients who were not diagnosed with BIA-ALCL until after those dates, the clock typically begins running at diagnosis rather than at the recall. Patients who received no notification of the recall from their surgeon — or who only discovered the connection between their implants and their symptoms upon diagnosis — may have strong delayed-discovery arguments even in 2026. Women who are still monitoring recalled implants that have not been removed and later receive a BIA-ALCL diagnosis will have their limitations period begin at diagnosis. MDL 2921 tolling agreements negotiated between plaintiffs and Allergan have preserved many claims that might otherwise be time-barred, but new claimants should not rely on MDL tolling without confirmed enrollment. Whether that time has passed depends on your facts, so don't rule yourself out. A lawyer can tell you.

A Texas woman received Natrelle 410 implants in 2012 for cosmetic augmentation, received no recall notification from her surgeon, and was diagnosed with Stage II BIA-ALCL in March 2025 after presenting with late-onset seroma.

Texas has a 2-year statute of limitations for personal injury (Tex. Civ. Prac. & Rem. Code § 16.003) with a discovery rule. The claimant's BIA-ALCL diagnosis in March 2025 is the discovery date — she had no reasonable means to know earlier. Her Texas filing deadline is approximately March 2027. A lawyer can confirm how that deadline applies to her facts.

California has a 2-year statute under CCP § 335.1 with discovery rule. The claimant knew of the recall basis for her explant in November 2019; her California deadline was approximately November 2021 for explant costs. Whether that time has passed depends on her facts, including any MDL 2921 tolling and arguments about inadequate recall notice, so she shouldn't rule herself out. A California lawyer can tell her.

Women who received Allergan BIOCELL textured breast implants — whether for cosmetic augmentation or post-mastectomy reconstruction — can ask a lawyer to check which deadline applies to them. Earlier diagnoses or explant-only claims need a careful look at the discovery rule and any MDL tolling. Whether that time has passed depends on your facts, so don't rule yourself out. A lawyer can tell you.